Breaking news

Novartis Acquires Blackstone’s Anthos Therapeutics For Up To $3.1 Billion To Strengthen Cardiovascular Portfolio

by THEFUTURE.TEAM

February 11, 2025

Swiss pharmaceutical giant Novartis has struck a deal to acquire Anthos Therapeutics, a biopharma company majority-owned by Blackstone’s drug development arm, for up to $3.1 billion. The acquisition is aimed at bolstering Novartis’ presence in the cardiovascular sector, a key focus for the company as its blockbuster heart failure drug Entresto faces patent expiration this year.

Founded in 2019 by Blackstone’s Life Sciences division and Novartis, Anthos was created to develop abelacimab, a promising treatment designed to prevent strokes and prevent recurring blood clots. This transaction underscores Novartis’ commitment to cardiovascular treatments, which is one of five critical therapeutic areas the company is prioritizing.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

The deal, which is expected to close by mid-2025, marks a significant step in the evolving partnership between a major pharmaceutical company and private equity, a model that has gained traction in the industry. Novartis will pay an initial $925 million, with potential additional payments up to $2.15 billion, contingent on the successful development of the therapy.

This marks the largest sale of a majority-owned company by Blackstone’s Life Sciences division to date. In December 2023, Blackstone was exploring the sale of Anthos, and the current deal brings the partnership to a close.

Abelacimab is part of a new class of anticoagulants known as factor XI inhibitors, designed to potentially replace established blood thinners like Eliquis (Bristol Myers-Squibb and Pfizer) and Xarelto (Johnson & Johnson and Bayer), both of which are billion-dollar sellers. Other major companies in the factor XI race include Bristol-Myers Squibb and Johnson & Johnson, who are advancing a similar drug candidate, as well as Merck & Co, which is progressing with a mid-stage development candidate. Bayer, meanwhile, faced a setback in 2023 with its factor XI drug.

Nicholas Galakatos, Chairman of Anthos’ board and Global Head of Blackstone Life Sciences expressed pride in the firm’s role in launching and growing Anthos, adding, “We believe abelacimab has the potential to be a leader in the new class of Factor XI anticoagulants and are pleased to have Novartis as a committed partner to advance the development and commercialization of abelacimab for millions of patients at risk of strokes.”

Anthos is currently conducting multiple Phase 3 clinical trials, with data expected in the second half of 2026. While Novartis holds a small minority equity stake in Anthos, the company has not disclosed the exact size of this investment.

The Decline Of Smartwatches: A Turning Point In The Wearable Tech Industry

by THEFUTURE.TEAM

March 13, 2025

For the first time in history, the smartwatch market is facing a significant downturn. Shipments are expected to drop by 7% in 2024, marking a major shift in a segment that has been growing steadily for over a decade. A report by Counterpoint reveals that while Apple still holds the top spot, its dominance is being challenged by a surge from Chinese brands like Huawei, Xiaomi, and BBK. Even as the overall market struggles, some companies are thriving.

The Big Picture: Why Smartwatches Are Slowing Down

Apple’s flagship products have long been the driving force in the smartwatch market, but even the tech giant is feeling the pressure. The company’s shipments are projected to fall by 19% this year, though it will remain the market leader. Meanwhile, brands from China are capitalizing on the shift, with Huawei showing an impressive 35% growth in sales, driven by the booming domestic market and a broad range of offerings, including smartwatches for kids.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Xiaomi, too, is experiencing remarkable success, with a staggering 135% increase in sales. In contrast, Samsung is seeing more modest growth, up 3%, thanks to its latest Galaxy Watch 7 and Galaxy Watch Ultra series.

While some companies are succeeding, the broader market is facing headwinds. The biggest factor behind the overall decline is the slowdown in India, where consumer demand for smartwatches has stagnated. The segment is suffering from a lack of innovation and fresh updates, leaving many consumers with little incentive to upgrade their devices. Add to that market saturation, and it’s clear why many users are content with their current models. The Chinese market, however, is bucking the trend, showing 6% growth in 2024.

A Glimpse Into The Future

Looking ahead, the smartwatch market may begin to recover in 2025, driven by the increasing integration of AI and advanced health monitoring tools. As these technologies evolve, the industry could see a resurgence in demand.

Huawei’s Remarkable Comeback

Huawei’s impressive performance in the smartwatch space signals a broader recovery for the company, which has been hit hard by US sanctions. Once the world’s largest smartphone maker, Huawei’s business was decimated when it lost access to advanced chips and Google’s Android operating system in 2019. But in China, Huawei has maintained its dominance, with its market share growing to 17% in 2024.

This resurgence was partly driven by the launch of the Mate 60 Pro, a smartphone featuring a 7-nanometer chip developed in China. Despite US sanctions, the device surprised many with its capabilities, a testament to China’s rising investment in domestic semiconductor production.

In February, Huawei also unveiled its Mate XT foldable smartphone, the world’s first device to fold in three directions. Running on HarmonyOS 4.2, Huawei’s proprietary operating system, the phone further demonstrates the company’s resilience and ability to innovate despite international challenges.

Huawei’s smartwatch offerings are also catching attention, particularly the Huawei Watch GT 5 Pro, which launched in September of last year. With a premium titanium alloy design, a high-resolution AMOLED display, and impressive health tracking features, the GT 5 Pro has become a standout in the market, available to both Android and iOS users.

A Brief History Of The Smartwatch Revolution

The smartwatch market has had its fair share of milestones, but the real breakthrough came in 2012 with the Pebble, a Kickstarter-funded project that raised over $10 million. Pebble introduced the world to smartphone integration, app downloads, and long battery life, becoming the first truly mass-market smartwatch.

In 2013, Samsung entered the game with the Galaxy Gear, marking its first attempt at wearable tech. But it was Apple’s entry in 2014 that truly set the industry on fire. The Apple Watch’s sleek design, integration with iOS, and emphasis on health and fitness catapulted it to the top of the market, establishing a standard that many other brands would try to follow.

By 2021, the smartwatch industry had grown to over $30 billion in revenue, with annual growth reaching 20%. Yet now, it finds itself at a crossroads, with innovation stagnating and market saturation taking a toll.